

Use of antipsychotics and risk of breast cancer: a Danish

British Journal of Clinical Pharmacology

84, 2152-2161

DOI: [10.1111/bcp.13661](https://doi.org/10.1111/bcp.13661)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Use of antipsychotics and risk of breast cancer: a Danish nationwide case-control study. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2152-2161.	1.1	37
2	Breast cancer risk associated with antipsychotic use. <i>The Brown University Psychopharmacology Update</i> , 2019, 30, 2-2.	0.1	3
3	Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1598-1606.	1.1	38
4	Psychotropic Medication Use and Postmenopausal Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 254-256.	1.1	11
5	ERK/AKT Inactivation and Apoptosis Induction Associate With Quetiapine-inhibited Cell Survival and Invasion in Hepatocellular Carcinoma Cells. <i>In Vivo</i> , 2020, 34, 2407-2417.	0.6	11
6	Post-diagnostic antipsychotic use and cancer mortality: a population based cohort study. <i>BMC Cancer</i> , 2020, 20, 804.	1.1	8
7	Neuroleptic malignant syndrome in patients with cancer: a systematic review. <i>BMJ Supportive and Palliative Care</i> , 2020, 10, 265-270.	0.8	3
8	Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 862-871.	0.5	7
9	A systematic review of quantitative bias analysis applied to epidemiological research. <i>International Journal of Epidemiology</i> , 2021, 50, 1708-1730.	0.9	11
10	Effect of antipsychotics on breast tumors by analysis of the Japanese Adverse Drug Event Report database and cell-based experiments. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2021, 7, 13.	0.4	2
12	New Insight into Breast Cancer Cells Involving Drug Combinations for Dopamine and Serotonin Receptors. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 6082.	1.3	2
13	Multifaceted effect of chlorpromazine in cancer: implications for cancer treatment. <i>Oncotarget</i> , 2021, 12, 1406-1426.	0.8	10
14	Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. <i>Lancet Psychiatry</i> , 2021, 8, 883-891.	3.7	50
15	Antipsychotic medication for women with schizophrenia spectrum disorders. <i>Psychological Medicine</i> , 2022, 52, 649-663.	2.7	30
16	The Risk of Antipsychotic Drugs on Breast Cancer: A Systematic Review and Meta-analysis. <i>Oman Medical Journal</i> , 2022, 37, e453-e453.	0.3	1
17	Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors. <i>European Journal of Endocrinology</i> , 2022, 186, P1-P33.	1.9	26
18	Risk of Breast Cancer With Prolactin Elevating Antipsychotic Drugs. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 7-16.	0.7	23
19	Towards better care for women with schizophrenia-spectrum disorders. <i>Lancet Psychiatry</i> , 2022, 9, 330-336.	3.7	24

#	ARTICLE	IF	CITATIONS
20	Cancer incidence and stage at diagnosis among people with recent-onset psychotic disorders: A retrospective cohort study using health administrative data from Ontario, Canada. <i>Psycho-Oncology</i> , 2022, 31, 1510-1518.	1.0	3
21	Prevalence of Heavy Menstrual Bleeding and Its Associated Cognitive Risks and Predictive Factors in Women With Severe Mental Disorders. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
22	Haloperidol and Other Antipsychotics Exposure before Endometrial Cancer Diagnosis: A Population-based Case-control Study. <i>Clinical Psychopharmacology and Neuroscience</i> , 2022, 20, 526-535.	0.9	0
23	Cancer incidence and stage at diagnosis among people with psychotic disorders: Systematic review and meta-analysis. <i>Cancer Epidemiology</i> , 2022, 80, 102233.	0.8	10
24	Association of antipsychotic use with breast cancer: a systematic review and meta-analysis of observational studies with over 2 million individuals. <i>Epidemiology and Psychiatric Sciences</i> , 2022, 31, .	1.8	5
25	A Meta-Analysis of Antipsychotic-Induced Hypo- and Hyperprolactinemia in Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2022, 32, 374-389.	0.7	8
26	Risk-to-benefit ratios of consecutive antidepressants for heavy menstrual bleeding in young women with bipolar disorder or major depressive disorder. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	1
27	Risk of Breast Cancer in Association with the Use of Second-generation Antipsychotics. <i>Clinical Psychopharmacology and Neuroscience</i> , 2022, 20, 675-684.	0.9	1
28	Antipsychotic exposure is an independent risk factor for breast cancer: A systematic review of epidemiological evidence. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
29	A preliminary study to identify existing drugs for potential repurposing in breast cancer based on side effect profile. <i>Drug Research</i> , 2023, 73, 296-303.	0.7	0
30	Association between long-term use of prolactin-elevating antipsychotics in women and the risk of breast cancer: What are the clinical implications?. <i>Australasian Psychiatry</i> , 2023, 31, 205-208.	0.4	1
33	Medications for Psychosis: Dopamine Blockers and Dopamine Partial Agonists (Antipsychotics). , 2023, , 1-58.		0